Nuvation Bio Q4 Earnings Call Highlights [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
in 2025 (216 in Q4) and prescriptions ramping roughly six times faster than prior ROS1 TKI launches, though early use skewed to later-line patients has limited near-term revenue conversion. Safusidenib has launched the global pivotal Phase III SIGMA trial (300 patients) as maintenance therapy for IDH1-mutant glioma with a 2029 readout expected, plus a ~40-patient oligodendroglioma cohort due in 2027 that could support accelerated approval if ORR is strong. Nuvation reported Q4 revenue of $41.9M and full-year $62.9M (IBTROZI U.S. net product revenue of $15.7M in Q4), ended 2025 with about $529M in cash and available financing and said it does not expect to need additional external funding to reach profitability. Interested in Nuvation Bio Inc.? Here are five stocks we like better. Nuvation Bio (NYSE:NUVB) executives highlighted the company's first full year of commercial activity for IBTROZI and outlined late-stage development plans for safusidenib during the company's fourth-q
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio (NUVB) had its price target lowered by UBS Group AG from $10.00 to $7.00. They now have a "neutral" rating on the stock.MarketBeat
NUVB
Earnings
- 3/2/26 - In-Line
NUVB
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- NUVB's page on the SEC website